- Home
- COLL
as 02-21-2025 12:34pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Upcoming Earnings Alert:
Get ready for potential market movements as Collegium Pharmaceutical Inc. COLL prepares to release earnings report on 27 Feb 2025.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.0B | IPO Year: | 2015 |
| Target Price: | $43.60 | AVG Volume (30 days): | 304.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.16 | EPS Growth: | 757.11 |
| 52 Week Low/High: | $28.39 - $42.29 | Next Earning Date: | 02-27-2025 |
| Revenue: | $599,245,000 | Revenue Growth: | 9.62% |
| Revenue Growth (this year): | 13.25% | Revenue Growth (next year): | 17.67% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Jan 10 '25 | Sell | $33.26 | 27,500 | $908,627.77 | 125,284 |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
COLL: Lowering target price to $31.00
GlobeNewswire
8 days ago
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
GlobeNewswire
16 days ago
Collegium Appoints Nancy S. Lurker to its Board of Directors
Argus Research
17 days ago
COLL: Lowering target price to $32.00
Argus Research
24 days ago
COLL: Lowering target price to $34.00
Argus Research
a month ago
COLL: What does Argus have to say about COLL?
MT Newswires
a month ago
Collegium Pharmaceutical Insider Sold Shares Worth $908,628, According to a Recent SEC Filing
MT Newswires
a month ago
Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.